• Entered the Gulf pharma market (Kuwait) as the first Bangladeshi company
• Became the first Bangladeshi company to commence medicine export to USA
• First Bangladeshi company to receive product approval from Health Canada

• First Bangladeshi pharma company audited and approved by the USFDA
• First product for USA approved
• Launched generic versions of blockbuster Hepatitis drugs Sofosbuvir and Sofosbuvir+Ledipasvir for the first time in the world

First Bangladeshi company to receive GMP approval from Health Canada and Taiwan Food and Drug Administration (TFDA)

First Bangladeshi company to export ophthalmic products to Europe

First Bangladeshi company to launch Salbutamol HFA inhaler (Azmasol^®) in Singapore

Received GMP accreditation from AGES, Austria (for European Union); only pharmaceutical company to win ‘National Export Trophy (Gold)’ for the fourth time

The only pharmaceutical company in Bangladesh to enter the US market through acquisition of an Abbreviated New Drug Application (ANDA)

Only Bangladeshi company to receive GMP approval from ANVISA, Brazil

First Bangladeshi company to receive GMP accreditation from Therapeutic Goods Administration (TGA), Australia, and Gulf Central Committee for Drug Registration, for GCC states; Technology transfer arrangement to manufacture Roche’s ARV drug Saquinavir

Launched CFC free HFA inhalers for the first time in Bangladesh

Only company in Bangladesh to be listed on the Alternative Investment Market (AIM) of London Stock Exchange (LSE) through issuance of GDRs

First company to introduce anti-retroviral (ARV) drugs in Bangladesh

Russia became the first export destination for formulation products

Export operations started with APIs

Listed on Dhaka Stock Exchange

Launched own formulation brands

Started manufacturing products of Bayer AG, Germany and Upjohn Inc., USA, under license agreements

Company incorporated